

Passion for Innovation.
Compassion for Patients.™



ASCO 2025 Highlights

DAIICHI SANKYO CO., LTD.

June 2nd (US)/ 3rd (JP), 2025

Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere.

This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.

ASCO Highlights 2025: IR conference call



Hiroyuki Okuzawa
President and CEO



Ken Takeshita
Head of Global R&D



Mark Rutstein
Head of Therapeutic Area
Oncology Development

Agenda

- ① Welcome message
- ② R&D overview
- ③ Highlights from ASCO 2025
- ④ Q&A



Agenda

1 **Welcome message**

2 R&D overview

3 Highlights from ASCO 2025

4 Q&A



Agenda

① Welcome message

② R&D overview


③ Highlights from ASCO 2025

④ Q&A



ASCO 2025

In our EXPAND strategy we showed ENHERTU footprint in earlier line




- Establish and expand DXd ADC therapies in **Breast** and **Lung** cancers
- **Go Earlier:** explore early lines of therapy/ stage of diseases; replace chemotherapy
- **Go Wider:** into new diseases beyond currently focusing areas to serve more patient needs


DESTINY
Breast09


DESTINY
Breast11

DESTINY-Breast05 to follow

Establish and expand DXd ADCs to address the broader spectrum of Breast Cancer



Launched

On-going


ENHERTU®

DATROWAY®

HER3-DXd

- Pivotal studies only, not exhaustive
- Box size does not reflect the patient population
- Box indicates current potential target segment

Establish and expand DXd ADCs to address the broader spectrum of Lung Cancer



- Pivotal studies and major Ph2 only, not exhaustive
- Box size does not reflect the patient population
- Box indicates current potential target segment

Agenda

1 Welcome message

2 R&D overview

3 Highlights from ASCO 2025

4 Q&A



Topics

ENHERTU®

- DESTINY-Breast09
- DESTINY-Gastric04

DATROWAY®

- TROPION-Lung02
- NeoCOAST-2

HER3-DXd

- HERTHENA-Lung02

Next Wave

- DS-2243

ENHERTU®

Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab (THP) for first-line treatment of patients with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer: interim results from DESTINY-Breast09

Sara M Tolaney, MD, MPH

Dana-Farber Cancer Institute, Boston, MA, US

Monday, June 2, 2025

Additional authors: Zefei Jiang, Qingyuan Zhang, Romualdo Barroso-Sousa, Yeon Hee Park, Mothaffar F Rimawi, Cristina Saura, Andreas Schneeweiss, Masakazu Toi, Yee Soo Chae, Yasemin Kemal, Mukesh Chaudhari, Toshinari Yamashita, Monica Casalnuovo, Michael A Danso, Jie Liu, Jagdish Shetty, Pia Herbolzheimer, Sibylle Loibl

On behalf of the DESTINY-Breast09 investigators

DESTINY-Breast09 study design


A randomized, multicenter, open-label,* Phase 3 study (NCT04784715)

Eligibility criteria

- HER2+ a/mBC
- Asymptomatic/inactive brain mets allowed
- DFI >6 mo from last chemotherapy or HER2-targeted therapy in neoadjuvant/adjuvant setting
- One prior line of ET for mBC permitted
- **No other prior systemic treatment for mBC[†]**

Stratification factors

- De-novo vs recurrent mBC
- HR+ or HR–
- *PIK3CA*m (detected vs non-detected)



Endpoints

Primary

- PFS (BICR)

Key secondary

- OS

Secondary

- PFS (INV)
- ORR (BICR/INV)
- DOR (BICR/INV)
- PFS2 (INV)
- Safety and tolerability

- If T-DXd was discontinued due to AEs (except Grade >2 ILD), patients could switch to trastuzumab**
- Concurrent use of ET (AI or tamoxifen) was allowed for those with HR+ disease after six cycles of T-DXd or discontinuation of taxane in THP arm

*Open label for THP arm. Double blinded for pertuzumab in experimental arms; [†]HER2-targeted therapy or chemotherapy; [‡]5.4 mg/kg Q3W; [§]840 mg loading dose, then 420 mg Q3W; [¶]paclitaxel 80 mg/m² QW or 175 mg/m² Q3W, or docetaxel 75 mg/m² Q3W for a minimum of six cycles or until intolerable toxicity; ^{||}8 mg/kg loading dose, then 6 mg/kg Q3W; **without loading dose

AE, adverse event; AI, aromatase inhibitor; a/mBC, advanced/metastatic breast cancer; BICR, blinded independent central review; DFI, disease-free interval; DOR, duration of response; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HER2+, HER2-positive; HR+/-, hormone receptor-positive/-negative; ILD, interstitial lung disease; INV, investigator; mets, metastases; mo, months; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PFS2, second progression-free survival; *PIK3CA*m, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha mutation; Q3W, every 3 weeks; QW, once every week; R, randomization; T-DXd, trastuzumab deruxtecan
NCT04784715. Updated. May 6, 2025. Available from: <https://clinicaltrials.gov/study/NCT04784715> (Accessed May 29, 2025)

DESTINY-Breast09 study design


A randomized, multicenter, open-label,* Phase 3 study (NCT04784715)

Eligibility criteria

- HER2+ a/mBC
- Asymptomatic/inactive brain mets allowed
- DFI >6 mo from last chemotherapy or HER2-targeted therapy in neoadjuvant/adjuvant setting
- One prior line of ET for mBC permitted
- **No other prior systemic treatment for mBC[†]**

Stratification factors

- De-novo vs recurrent mBC
- HR+ or HR–
- *PIK3CA*m (detected vs non-detected)



Endpoints

Primary

- PFS (BICR)

Key secondary

- OS

Secondary

- PFS (INV)
- ORR (BICR/INV)
- DOR (BICR/INV)
- PFS2 (INV)
- Safety and tolerability

At this planned interim analysis (DCO Feb 26, 2025), results are reported for the T-DXd + P and THP arms

*Open label for THP arm. Double blinded for pertuzumab in experimental arms; [†]HER2-targeted therapy or chemotherapy; [‡]5.4 mg/kg Q3W; [§]840 mg loading dose, then 420 mg Q3W; [¶]paclitaxel 80 mg/m² QW or 175 mg/m² Q3W, or docetaxel 75 mg/m² Q3W for a minimum of six cycles or until intolerable toxicity; ^{||}8 mg/kg loading dose, then 6 mg/kg Q3W

a/mBC, advanced/metastatic breast cancer; BICR, blinded independent central review; DCO, data cutoff; DFI, disease-free interval; DOR, duration of response; HER2, human epidermal growth factor receptor 2; HER2+, HER2-positive; HR+/- , hormone receptor-positive/-negative; INV, investigator; mBC, metastatic breast cancer; mets, metastases; mo, months; ORR, objective response rate; OS, overall survival; P, pertuzumab; PFS, progression-free survival; PFS2, second progression-free survival; *PIK3CA*m, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha mutation; Q3W, every 3 weeks; QW, once every week; R, randomization; T-DXd, trastuzumab deruxtecan NCT04784715. Updated. May 6, 2025. Available from: <https://clinicaltrials.gov/study/NCT04784715> (Accessed May 29, 2025)

Statistical analysis

Interim analysis for PFS by BICR

(planned after approximately 399 events across three arms, and at least 277 events per comparison)

- At this DCO (Feb 26, 2025), interim analysis criterion for superiority (P-value <0.00043) was already met for T-DXd + P vs THP (**maturity: ~38% of total N**)
- T-DXd + placebo remains blinded until final PFS analysis per protocol

First interim OS analysis

(prespecified)


- At DCO, 126 events had occurred (**maturity: ~16% of total N**)
- Final OS analysis will be conducted per protocol

Patient demographics and key baseline characteristics

	T-DXd + P (n=383)	THP (n=387)
Age, median (range), years	54 (27–85)	54 (20–81)
Female, n (%)	383 (100)	387 (100)
Geographical region, n (%)		
Asia	188 (49.1)	191 (49.4)
Western Europe and North America	87 (22.7)	78 (20.2)
Rest of World	108 (28.2)	118 (30.5)
ECOG performance status, n (%)		
0 (normal activity)	256 (66.8)	246 (63.6)
1 (restricted activity)	127 (33.2)	141 (36.4)
HER2 score by central test, n (%)		
IHC 3+	318 (83.0)	315 (81.4)
IHC <3 / ISH+	62 (16.2)	71 (18.3)
IHC NR / ISH+	3 (0.8)	1 (0.3)
HR status, n (%)		
Positive*	207 (54.0)	209 (54.0)
Negative	176 (46.0)	178 (46.0)
De-novo disease at diagnosis, n (%)	200 (52.2)	200 (51.7)
PIK3CA mutations detected, n (%)	116 (30.3)	121 (31.3)
Brain metastases, n (%)[†]	25 (6.5)	22 (5.7)
Visceral metastases, n (%)	281 (73.4)	268 (69.3)

*Defined as estrogen receptor–positive and/or progesterone receptor–positive (≥1%); [†]participants were eligible if they had brain metastases that were clinically inactive or treated/asymptomatic
ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; ISH, in situ hybridization; NR, not recorded; P, pertuzumab; T-DXd, trastuzumab deruxtecan;
THP, taxane + trastuzumab + pertuzumab


PFS (BICR): primary endpoint



Statistically significant and clinically meaningful PFS benefit with T-DXd + P (median Δ 13.8 mo)

*Median PFS estimate for T-DXd + P is likely to change at updated analysis; [†]stratified log-rank test. A P-value of <0.00043 was required for interim analysis superiority
 BICR, blinded independent central review; CI, confidence interval; mo, months; (m)PFS, (median) progression-free survival; NC, not calculable; P, pertuzumab; T-DXd, trastuzumab deruxtecan; THP, taxane + trastuzumab + pertuzumab


PFS (investigator assessment)



Clinically meaningful improvement in PFS with T-DXd + P over THP (median Δ 20.0 mo)

*Median PFS estimate for T-DXd + P is likely to change at updated analysis; [†]stratified log-rank test
 CI, confidence interval; mo, months; (m)PFS, (median) progression-free survival; NC, not calculable; P, pertuzumab; T-DXd, trastuzumab deruxtecan; THP, taxane + trastuzumab + pertuzumab

PFS (BICR): subgroup analyses




Size of circle is proportional to the number of events
 BICR, blinded independent central review;
 CI, confidence interval; HER2, human epidermal
 growth factor receptor 2; HR, hormone receptor;
 NC, not calculable; P, pertuzumab;
 (m)PFS, (median) progression-free survival;
 T-DXd, trastuzumab deruxtecan;
 THP, taxane + trastuzumab + pertuzumab

PFS benefit with T-DXd + P vs THP was consistently observed across prespecified subgroups, including stratification factors

ORR and DOR

Confirmed ORR*




	T-DXd + P (n=383)	THP (n=387)
Median DOR, mo (95% CI)	39.2 (35.1, NC)	26.4 (22.3, NC)
Remaining in response at 24 mo (%)	73.3	54.9
Stable disease, n (%)	38 (9.9)	56 (14.5)

Response rates were greater with T-DXd + P vs THP and were durable

*Based on RECIST v1.1; response required confirmation after 4 weeks
 BICR, blinded independent central review; CI, confidence interval; CR, complete response; DOR, duration of response; mo, months; NC, not calculable; ORR, objective response rate; P, pertuzumab; PR, partial response;
 RECIST, Response Evaluation Criteria in Solid Tumours; T-DXd, trastuzumab deruxtecan; THP, taxane + trastuzumab + pertuzumab

Overall survival (~16% maturity)



Early OS data suggest a positive trend favoring T-DXd + P over THP

CI, confidence interval; (m)OS, (median) overall survival; NC, not calculable; P, pertuzumab; T-DXd, trastuzumab deruxtecan; THP, taxane + trastuzumab + pertuzumab

Overall safety summary

	Safety analysis set*	
	T-DXd + P (n=381)	THP (n=382)
Total exposure, patient years	659.7	564.0
Any TEAE, n (%)	380 (99.7)	378 (99.0)
Possibly treatment-related TEAEs (investigator assessed), n (%) Grade ≥3	373 (97.9) 209 (54.9)	369 (96.6) 200 (52.4)
Serious TEAEs, n (%)	103 (27.0)	96 (25.1)
TEAEs associated with any treatment discontinuation,[†] n (%)	79 (20.7)	108 (28.3)
TEAEs associated with any dose interruptions,[†] n (%)	262 (68.8)	187 (49.0)
TEAEs associated with any dose reductions,[†] n (%)	175 (45.9)	76 (19.9)
TEAEs with outcome of death, n (%) Possibly treatment related (investigator assessed) [‡]	13 (3.4) 5 (1.3)	3 (0.8) 1 (0.3)

Median total treatment duration:

- **T-DXd + P: 21.7 mo (range 0.3–44.5)**
 - T-DXd: 20.0 mo[§]
- **THP: 16.9 mo (range 0.7–41.7)**

Median treatment duration for taxanes:


- Docetaxel: 5.5 mo (range 0.7–37.4)
- Paclitaxel: 4.4 mo (range 0.2–30.7)

Median number of cycles for taxanes:

- Docetaxel: 8 (range 1–51)
- Paclitaxel: 6 (range 1–42)

*Safety analyses included all patients who received at least one dose of study treatment (at least one study drug); [†]dose modifications or discontinuations relate to any component of each arm; [‡]treatment-related TEAEs with outcome of death were pneumonitis (n=1), sepsis (n=1), septic shock (n=1), febrile neutropenia (n=1), and dyspnea (n=1) in the T-DXd + P arm, and anemia (n=1) in the THP arm; [§]excludes data from the 8.7% (33/380) of treated patients who received trastuzumab after discontinuing T-DXd due to TEAEs
mo, months; P, pertuzumab; T-DXd, trastuzumab deruxtecan; TEAE, treatment-emergent adverse event; THP, taxane + trastuzumab + pertuzumab

Possibly treatment-related (investigator assessed) TEAEs in ≥20% of patients (either arm)



*Antiemetic prophylaxis was recommended but not mandated by protocol; †neutropenia (grouped term) includes: neutropenia and neutrophil count decreased; ‡fatigue (grouped term) includes: fatigue, asthenia, malaise, and lethargy; §transaminases increased (grouped term) includes: transaminases increased, aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased, liver function test abnormal, hepatic function abnormal, and liver function test increase; ¶anemia (grouped term) includes: anemia, hemoglobin decreased, hematocrit decreased, and red blood cell count decreased; ||leukopenia (grouped term) includes: leukopenia and white blood cell count decreased; **thrombocytopenia (grouped term) includes: platelet count decreased and thrombocytopenia; ††peripheral sensory neuropathy (grouped term) includes: neuropathy peripheral, peripheral sensory neuropathy, and polyneuropathy

P, pertuzumab; T-DXd, trastuzumab deruxtecan; TEAE, treatment-emergent adverse event; THP, taxane + trastuzumab + pertuzumab

Adverse events of special interest

Adjudicated drug-related ILD/pneumonitis*

n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Any grade
T-DXd + P (n=381)	17 (4.5)	27 (7.1)	0	0	2 (0.5)	46 (12.1)
THP (n=382)	2 (0.5)	2 (0.5)	0	0	0	4 (1.0)

Left ventricular dysfunction†

n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Any grade
T-DXd + P (n=381)	4 (1.0)	30 (7.9)	7 (1.8)	1 (0.3)	0	42 (11.0)
THP (n=382)	1 (0.3)	19 (5.0)	7 (1.8)	0	0	27 (7.1)

Safety analysis set

*Adjudicated drug-related ILD/pneumonitis (grouped term) includes: chronic obstructive pulmonary disease, interstitial lung disease, organizing pneumonia, pneumonia, and pneumonitis, †left ventricular dysfunction (grouped term) includes: potential heart failure, cardiac failure, cardiac failure chronic, ejection fraction decreased, left ventricular dysfunction, and right ventricular failure
ILD, interstitial lung disease; P, pertuzumab; T-DXd, trastuzumab deruxtecan; THP, taxane + trastuzumab + pertuzumab

Conclusions

- T-DXd + P demonstrated a **statistically significant and clinically meaningful PFS benefit** by BICR vs THP, which was consistently observed across subgroups
 - Hazard ratio of **0.56** vs THP (**P<0.00001**)
 - Median PFS was **40.7 months (T-DXd + P)** vs **26.9 months (THP)**
- Median DOR of **>3 years with T-DXd + P**, with CRs in **15.1% (T-DXd + P)** vs **8.5% (THP)**
- Early OS data suggest a positive trend favoring T-DXd + P, with a supportive hazard ratio of **0.60** for PFS2
- T-DXd + P safety data were **consistent with known profiles of individual treatments**

PFS by BICR

44%

**Reduction in risk of
disease progression
or death with
T-DXd + P vs THP**

T-DXd + P demonstrated a statistically significant and clinically meaningful PFS benefit vs THP and may represent a new first-line standard of care for patients with HER2+ a/mBC

a/mBC, advanced/metastatic breast cancer; BICR, blinded independent central review; CR, complete response; DOR, duration of response; HER2+, human epidermal growth factor receptor 2-positive; OS, overall survival; P, pertuzumab; PFS, progression-free survival; PFS2, second progression-free survival; T-DXd, trastuzumab deruxtecan; THP, taxane + trastuzumab + pertuzumab

Trastuzumab deruxtecan vs ramucirumab plus paclitaxel in second-line treatment of patients with human epidermal growth factor receptor 2–positive (HER2+) unresectable and/or metastatic gastric cancer or gastroesophageal junction adenocarcinoma: Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study

Kohei Shitara

National Cancer Center Hospital East, Kashiwa, Japan

Additional authors: Mahmut Gümüş, Filippo Pietrantonio, Sara Lonardi, Christelle de la Fouchardière, Clélia Coutzac, Jeroen Dekervel, Daniel Hochhauser, Lin Shen, Wasat Mansoor, Bo Liu, Lorenzo Fornaro, Min-Hee Ryu, Jeeyun Lee, Fabricio Souza, Lori Jukofsky, Yumin Zhao, Takahiro Kamio, Meredith Venerus, Aziz Zaanani, Eric Van Cutsem

On behalf of the DESTINY-Gastric04 investigators

Current Treatment Landscape in HER2+ Metastatic GC/GEJA

- An estimated 5%-17% of GCs are HER2+ (IHC 3+ or IHC 2+/ISH+) ¹⁻⁴
- 1L therapy for patients with HER2+ metastatic GC/GEJA is chemotherapy plus trastuzumab, with pembrolizumab if PD-L1 is expressed (CPS ≥ 1) ⁵
- Results from the phase 2 DESTINY-Gastric01/02/06 trials led to the approval of T-DXd in the 2L+ setting in patients with HER2+ metastatic GC/GEJA ⁶⁻⁸
- The combination of RAM + PTX is the SOC in 2L GC/GEJA based on results from the phase 3 RAINBOW trial ⁹


DESTINY-Gastric04 was conducted to evaluate T-DXd in a head-to-head phase 3 trial versus RAM + PTX in patients with HER2+ metastatic GC/GEJA

1L, first-line; 2L, second-line; CPS, combined positive score; GC, gastric cancer; GEJA, gastroesophageal junction adenocarcinoma; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; PD-L1, programmed death ligand 1; PTX, paclitaxel; RAM, ramucirumab; SOC, standard of care; T-DXd, trastuzumab deruxtecan.

1. Uzunparmak B et al. *Ann Oncol.* 2023;34:1035-46. 2. Van Cutsem E et al. *Gastric Cancer.* 2015;18:476-84. 3. Subasinghe D et al. *J Int Med Res.* 2023;51:03000605231154403. 4. Bartley AN et al. *J Oncol Pract.* 2017;13:53-7. 5. ESMO Gastric Cancer Living Guideline v1.4 September 2024. European Society for Medical Oncology, 2024. (Accessed April 2, 2025, at <https://www.esmo.org/living-guidelines/esmo-gastric-cancer-living-guideline>). 6. Shitara K et al. *N Engl J Med.* 2020;382:2419-30. 7. Van Cutsem E et al. *Lancet Oncol.* 2023;24:744-56. 8. Shen L et al. *Ann Oncol.* 2023;34:S1542-3. 9. Wilke H et al. *Lancet Oncol.* 2014;15:1224-35.

Study Design

DESTINY-Gastric04: A Global, Multicenter, Randomized, Phase 3 Trial (NCT04704934)



1L, first-line; ASCO/CAP, American Society of Clinical Oncology/College of American Pathologists; CNS, central nervous system; DCR, disease control rate; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; EORTC, European Organisation for Research and Treatment of Cancer; EQ-5D-5L, EuroQol 5-Dimension, 5-Level; FACT-Ga, Functional Assessment of Cancer Therapy-gastric; GC, gastric cancer; GEJA, gastroesophageal junction adenocarcinoma; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; INV, investigator; ISH, in situ hybridization; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PRO, patient-reported outcome; PTX, paclitaxel; Q3W, every 3 weeks; R, randomization; RAM, ramucirumab; RECIST v1.1, Response Evaluation Criteria in Solid Tumours, version 1.1; T-DXd, trastuzumab deruxtecan; VAS, visual analog scale.

^aAs classified by the 2017 ASCO-CAP guidelines for HER2 testing in gastroesophageal adenocarcinoma. ^bStudy protocol originally mandated HER2 status be determined centrally but was later amended to allow local determination. ^cClinically active CNS metastases were defined as being untreated and symptomatic or requiring therapy with corticosteroids or anticonvulsants. Patients with clinically inactive CNS metastases could be enrolled. ^dRAM administered as 8 mg/kg on days 1 and 15 of each 28-day cycle and PTX administered as 80 mg/m² on days 1, 8, and 15 of each 28-day cycle. ^eDetermined by investigator-based assessment on RECIST v1.1. ^fBased on EORTC EQ-5D-5L VAS and FACT-Ga subscales.

Statistical Analysis


Planned sample size: 490

- 339 OS events were needed to ensure 90% power to detect an OS hazard ratio of 0.70 (overall 2-sided α error of 5%^a)

Interim OS analysis (planned after enrollment completion and 237 OS events [$\sim 70\%$ ^b])

- OS, PFS, and confirmed ORR were tested hierarchically using a gatekeeping procedure to control for multiplicity^c
- At DCO (October 24, 2024), there were 266 OS events and 322 investigator-assessed PFS events
- The superiority stopping boundary for OS was achieved at this interim analysis making this the primary analysis (2-sided $P < 0.0228^d$)

Hierarchical testing



DCO, data cutoff; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.

^a1-sided error of 2.5%. ^bInformation fraction. ^cTesting for these endpoints proceeded if the previous endpoint in the hierarchy was statistically significant. ^dCalculated based on the number of deaths by Lan-DeMets alpha-spending function, with an O'Brien-Fleming boundary.

Demographics and Baseline Characteristics

	T-DXd n = 246	RAM + PTX n = 248
Age, median (range), years	63.2 (21.1-84.1)	64.3 (31.9-87.0)
Male, n (%)	187 (76.0)	205 (82.7)
Geography,^a n (%)		
Asia (excluding mainland China)	57 (23.2)	60 (24.2)
Western Europe	140 (56.9)	139 (56.0)
Mainland China/ROW	49 (19.9)	49 (19.8)
Race, n (%)		
White	116 (47.2)	130 (52.4)
Black/African American	0	2 (0.8)
Asian	101 (41.1)	97 (39.1)
Other	28 (11.4)	19 (7.7)
ECOG PS, n (%)		
0 1	97 (39.4) 148 (60.2)	88 (35.5) 158 (63.7)
2 missing	1 (0.4) 0	1 (0.4) 1 (0.4)
Primary tumor location, n (%)		
Gastric	153 (62.2)	149 (60.1)
GEJ	93 (37.8)	99 (39.9)

	T-DXd n = 246	RAM + PTX n = 248
HER2 status,^{a,b} n (%)		
IHC 2+/ISH+	39 (15.9)	40 (16.1)
IHC 3+	207 (84.1)	208 (83.9)
Time to progression on 1L therapy,^a n (%)		
<6 months	61 (24.8)	61 (24.6)
≥6 months	185 (75.2)	187 (75.4)
Prior treatment with ICI, n (%)		
Yes	39 (15.9)	38 (15.3)
No	207 (84.1)	210 (84.7)
Metastatic sites, n (%)		
<2	73 (29.7)	75 (30.2)
≥2	173 (70.3)	173 (69.8)
Presence of liver metastases, n (%)	147 (59.8)	158 (63.7)
Presence of brain metastases, n (%)	16 (6.5)	18 (7.3)

1L, first-line; ECOG PS, Eastern Cooperative Oncology Group performance status; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; ICI, immune checkpoint inhibitor; IHC, immunohistochemistry; ISH, in situ hybridization; PTX, paclitaxel; RAM, ramucirumab; ROW, rest of world; T-DXd, trastuzumab deruxtecan.

^aStratification factor by interactive response technology. ^bLocal or central HER2 status.

© Copyright 2025.

Subsequent Anticancer Therapy

	T-DXd n = 246	RAM + PTX n = 248
Patients receiving any subsequent systemic anticancer treatment,^a n (%)	126 (51.2)	118 (47.6)
Paclitaxel	63 (25.6)	8 (3.2)
Ramucirumab	43 (17.5)	8 (3.2)
Irinotecan	16 (6.5)	16 (6.5)
Nivolumab	14 (5.7)	14 (5.6)
Paclitaxel nanoparticle albumin-bound	13 (5.3)	0
Paclitaxel; ramucirumab	13 (5.3)	3 (1.2)
Trastuzumab	12 (4.9)	8 (3.2)
Calcium folinate; fluorouracil; irinotecan hydrochloride	11 (4.5)	12 (4.8)
Tipiracil hydrochloride; trifluridine	11 (4.5)	11 (4.4)
Fluorouracil	10 (4.1)	11 (4.4)
Oxaliplatin	10 (4.1)	1 (0.4)
Disitamab vedotin	5 (2.0)	12 (4.8)
Trastuzumab deruxtecan	3 (1.2)	52 (21.0)

- Of patients who discontinued study treatment from the RAM + PTX arm, 52 (21.0%) received T-DXd and 12 (4.8%) received disitamab vedotin as subsequent systemic anticancer therapy


PTX, paclitaxel; RAM, ramucirumab; T-DXd, trastuzumab deruxtecan.

Received by ≥4% of patients in either arm, listed in descending order in the T-DXd arm.

^aPatients may have received more than 1 type of subsequent anticancer therapy.

© Copyright 2025.

OS: Primary Endpoint



T-DXd demonstrated a statistically significant and clinically meaningful improvement in OS compared with RAM + PTX in HER2+ GC/GEJA, showing a 30% reduction in risk of death


DCO, data cutoff; GC, gastric cancer; GEJA, gastroesophageal junction adenocarcinoma; HER2, human epidermal growth factor receptor 2; mOS, median overall survival; OS, overall survival; PTX, paclitaxel; RAM, ramucirumab; T-DXd, trastuzumab deruxtecan.

At DCO (October 24, 2024), the median duration of OS follow-up was 16.8 months for T-DXd and 14.4 months for RAM + PTX. Boundary for superiority: 2-sided *P* < 0.0228.

^aTwo-sided *P* value from stratified log-rank test and stratified Cox proportional hazards model adjusted for stratification factor: HER2 status (IHC 3+ or IHC 2+/ISH+).


© Copyright 2025.

OS by Subgroups



1L, first-line; ECOG PS, Eastern Cooperative Oncology Group performance status; GEJA, gastroesophageal junction adenocarcinoma; HER2, human epidermal growth factor receptor 2; ICI, immune checkpoint inhibitor; IHC, immunohistochemistry; ISH, in situ hybridization; OS, overall survival; PTX, paclitaxel; RAM, ramucirumab; ROW, rest of world; T-DXd, trastuzumab deruxtecan.
© Copyright 2025.

PFS by Investigator: Key Secondary Endpoint



T-DXd demonstrated a statistically significant improvement in PFS compared with RAM + PTX in HER2+ GC/GEJA, showing a 26% reduction in risk of progression or death

GC, gastric cancer; GEJA, gastroesophageal junction adenocarcinoma; HER2, human epidermal growth factor receptor 2; mPFS, median progression-free survival; PFS, progression-free survival; PTX, paclitaxel; RAM, ramucirumab; T-DXd, trastuzumab deruxtecan.


Boundary for superiority: 2-sided $P < 0.0185$.

^aTwo-sided P value from stratified log-rank test and stratified Cox proportional hazards model adjusted for stratification factor: HER2 status (IHC 3+ or IHC 2+/ISH+).

© Copyright 2025.

Confirmed ORR and DOR^{a,b}

	T-DXd n = 246	RAM + PTX n = 248
Confirmed ORR (95% CI),^c %	44.3 (37.8-50.9)	29.1 (23.4-35.3)
<i>P</i> value ^d	0.0006	
Difference (95% CI), ^e %	15.1 (6.1-24.2)	
DOR, median (95% CI), mo	7.4 (5.7-10.1)	5.3 (4.1-5.7)
DCR (95% CI), %	91.9 (87.7-95.1)	75.9 (70.0-81.2)
Confirmed BOR, n (%)		
CR ^f	7 (3.0)	3 (1.3)
PR	97 (41.3)	66 (27.8)
SD ^g	112 (47.7)	111 (46.8)
PD	13 (5.5)	22 (9.3)
NE	6 (2.6)	35 (14.8)



The confirmed ORR was 15.1% greater with T-DXd compared with RAM + PTX ($P = 0.0006$), with longer DOR

BOR, best overall response; CR, complete response; DCO, data cutoff; DCR, disease control rate; DOR, duration of response; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; NE, not evaluable; PD, progressive disease; PR, partial response; ORR, objective response rate; PTX, paclitaxel; RAM, ramucirumab; SD, stable disease; T-DXd, trastuzumab deruxtecan.

ORR eligible patients are those who were randomly assigned at least 77 days (ie, 2×6 weeks - 1 week) before DCO date of interim analyses. Confirmed BOR, ORR, and DCR are calculated using the eligible patients as the denominator.

^aBased on investigator assessment. ^bBased on ORR eligible patients. ^cBased on Clopper-Pearson method for single proportion. ^dStratified analysis using the Cochran-Mantel-Haenszel test adjusted for stratification factor: HER2 status (IHC 3+ or IHC 2+/ISH+). ^e2-sided 95% CI for the difference in ORR is based on Wald method using continuity correction. ^fCR patients without target lesions at baseline were included. ^gNon-CR/non-PD patients without target lesions at baseline were included.

© Copyright 2025.

Overall Safety Summary

	Safety analysis set N = 477	
	T-DXd n = 244	RAM + PTX n = 233
Any TEAE, n (%)	244 (100)	228 (97.9)
Drug-related	227 (93.0)	213 (91.4)
Grade ≥3 TEAEs, n (%)	166 (68.0)	172 (73.8)
Drug-related	122 (50.0)	126 (54.1)
Serious TEAEs, n (%)	100 (41.0)	101 (43.3)
Drug-related	45 (18.4)	41 (17.6)
TEAEs associated with dose discontinuation, n (%)	35 (14.3)	40 (17.2)
Drug-related	28 (11.5)	31 (13.3)
TEAEs associated with dose interruption, n (%)	137 (56.1)	141 (60.5)
Drug-related	94 (38.5)	119 (51.1)
TEAEs associated with dose reduction, n (%)	77 (31.6)	87 (37.3)
Drug-related	76 (31.1)	84 (36.1)
TEAEs associated with death, n (%)	22 (9.0)	35 (15.0)
Drug-related ^a	4 (1.6)	2 (0.9)


- Median treatment duration:
 - **T-DXd:** 5.4 mo (range, 0.7-30.3 mo)
 - **RAM + PTX:** 4.6 mo (range, 0.9-34.9 mo)
- Similar incidence of drug-related grade ≥3 TEAEs, serious TEAEs, treatment discontinuations, and deaths were observed in the 2 arms

ILD, interstitial lung disease; mo, months; PTX, paclitaxel; RAM, ramucirumab; T-DXd, trastuzumab deruxtecan; TEAE, treatment-emergent adverse event.

^aDrug-related adverse events that were associated with death occurred in 4 patients (1.6%) who received T-DXd (upper gastrointestinal hemorrhage, intestinal obstruction, sudden death, and death not otherwise specified in 1 patient each) and in 2 patients (0.9%) who received RAM + PTX (gastric perforation and ILD in 1 patient each).

© Copyright 2025.

Drug-Related TEAEs in $\geq 10\%$ of Patients



- Most common drug-related TEAEs with T-DXd included fatigue or AEs of gastrointestinal or hematologic nature; for RAM + PTX, they included fatigue, neuropathy, and hematologic AEs

AE, adverse event; ILD, interstitial lung disease; PTX, paclitaxel; RAM, ramucirumab; T-DXd, trastuzumab deruxtecan; TEAE, treatment-emergent adverse event.

By preferred or grouped term in $\geq 10\%$ of patients with any-grade drug-related adverse event in either treatment arm.

^aIncludes fatigue, asthenia, malaise, and lethargy. ^bIncludes neutrophil count decreased and neutropenia. ^cIncludes hemoglobin decreased, red blood cell count decreased, anemia, and hematocrit decreased. ^dIncludes white blood cell count decreased and leukopenia. ^eIncludes platelet count decreased and thrombocytopenia. ^fIncludes transaminases increased, aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased, liver function test abnormal, hepatic function abnormal, and liver function test increased. ^gIncludes all adjudicated study drug-related events by the adjudication committee regardless of treatment-emergent events or not. ^hIncludes lymphocyte count decreased and lymphopenia. ⁱIncludes stomatitis, aphthous ulcer, mouth ulceration, oral mucosa erosion, oral mucosal blistering, and oral mucosal eruption. ^jIncludes peripheral sensory neuropathy, neuropathy peripheral, neurotoxicity, peripheral motor neuropathy, polyneuropathy.

AEs of Special Interest

Adjudicated drug-related ILD/pneumonitis

n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Any grade
T-DXd (n = 244)	7 (2.9)	26 (10.7)	1 (0.4)	0	0	34 (13.9)
RAM + PTX (n = 233)	0	0	2 (0.9)	0	1 (0.4)	3 (1.3)

Left ventricular dysfunction^a

n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Any grade
T-DXd (n = 244)	0	3 (1.2)	3 (1.2)	0	0	6 (2.5)
RAM + PTX (n = 233)	2 (0.9)	2 (0.9)	0	0	0	4 (1.7)

- ILD/pneumonitis events in the T-DXd arm were mainly low-grade, with no grade 4 or 5 events
 - Adjudicated drug-related ILD/pneumonitis occurred in 34 patients (13.9%) treated with T-DXd and 3 patients (1.3%) treated with RAM + PTX
- Incidence of left ventricular dysfunction was similar across both arms

AE, adverse event; ILD, interstitial lung disease; LVEF, left ventricular ejection fraction; PTX, paclitaxel; RAM, ramucirumab; T-DXd, trastuzumab deruxtecan.

^aIncludes preferred terms of ejection fraction decreased, cardiac failure, cardiac failure acute, cardiac failure congestive, and left ventricular dysfunction.

© Copyright 2025.

Conclusions

- **T-DXd demonstrated a statistically significant and clinically meaningful improvement in OS** compared with RAM + PTX in patients with HER2+ metastatic GC/GEJA in the 2L setting (median, 14.7 vs 11.4 months, respectively, with 30% reduction in risk of death: **HR, 0.70 [$P = 0.0044$]**)
- **Improvement in PFS, confirmed ORR, DCR, and DOR** was also observed **with T-DXd**
- The toxicity profile of T-DXd 6.4 mg/kg was generally manageable and was consistent with its known safety profile, with **no new safety signals identified**
 - Patient-reported QOL was maintained with T-DXd; scores were comparable in the T-DXd versus RAM + PTX arm
- Results support further evaluation of T-DXd in an earlier line setting

DESTINY-Gastric04 confirms T-DXd as the global 2L standard-of-care therapy for patients with HER2+ metastatic GC/GEJA

DATROWAY®

DATROWAY[®] : Combination Studies in NSCLC

DATROWAY[®] + Immune checkpoint inhibitors

pembrolizumab	TROPION-Lung02 w/o AGA	
	TROPION-Lung08* w/o AGA PD-L1 ≥50%, 1L	TROPION-Lung07 NSQ w/o AGA PD-L1 <50%, 1L
durvalumab	NeoCOAST-2 early stage, neoadjuvant	AVANZAR* w/o AGA, 1L
	TROPION-Lung04 w/o AGA	
rilvegostomig	TROPION-Lung12 stage1 high risk, adjuvant	TROPION-Lung10 w/o AGA PD-L1 ≥50%, 1L

DATROWAY[®] + tyrosine kinase inhibitors

osimertinib	ORCHARD EGFRm, 2L	
	TROPION-Lung14 EGFRm, 1L	TROPION-Lung15 EGFRm, 2L+

Ph3

Ph2

Ph1

* Due to the protocol revision, the inclusion criteria are limited to NSQ NSCLC

AGA: actionable genomic alteration, EGFRm: EGFR mutated, NSQ: non-squamous, NSCLC: non-small cell lung cancer

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC)

Benjamin P. Levy

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, MD, USA

Additional authors: Luis G. Paz-Ares, Chien-Chung Lin, Scott Herbert, Tsung-Ying Yang, Anthony W. Tolcher, Yanyan Lou, Yoshitaka Zenke, Diego Cortinovis, Enriqueta Felip, Manuel Domine Sr., Konstantinos Leventakos, Emiliano Calvo, Atsushi Horiike, Edward Pan, Keisuke Matsubara, Xiaoyu Jia, Rachel A. Chiaverelli, Michael J. Chisamore, Yasushi Goto

Phase 1b study of Dato-DXd + pembrolizumab ± Pt-CT in a/mNSCLC without actionable genomic alterations^a

Key eligibility criteria	1L patients only	Dato-DXd IV Q3W	+ Pembrolizumab IV Q3W	+ Pt-CT IV Q3W	Objectives	
<ul style="list-style-type: none">• a/mNSCLC• Dose escalation^b: ≤2 lines of prior therapy^c• Dose expansion<ul style="list-style-type: none">▪ ≤1 line of Pt-CT (cohorts 1 and 2)^c▪ Treatment-naïve (cohort 2)^{c,d}▪ Treatment-naïve (cohorts 3–6)^c	Cohort 1 (n=2):	4 mg/kg	+ 200 mg	Doublet	Primary: Safety and tolerability	
	Cohort 2 (n=40):	6 mg/kg	+ 200 mg			
	Cohort 3 (n=14):	4 mg/kg	+ 200 mg	+ Carboplatin AUC 5	Triplet	Secondary: Efficacy
	Cohort 4 (n=26):	6 mg/kg	+ 200 mg	+ Carboplatin AUC 5		
	Cohort 5 (n=8):	4 mg/kg	+ 200 mg	+ Cisplatin 75 mg/m ²		
	Cohort 6 (n=6):	6 mg/kg	+ 200 mg	+ Cisplatin 75 mg/m ²		

Data cutoff: April 29, 2024. Median study duration was 18.7 months (range, 11–33.8) for doublet and 24.6 months (range, 15.4–32.4) for triplet combinations.

^aPatients with known actionable genomic alterations in *EGFR*, *ALK*, *ROS1*, *NTRK*, *BRAF*, *RET*, or *MET*, or with alterations in other actionable oncogenic driver kinases were not eligible for this study. ^bThe first 3 to 6 patients in each cohort were enrolled to confirm acceptable safety/DLT rate; the remaining patients are considered part of dose expansion. ^cPrior therapy requirements are for treatment in the a/m setting.

^dEnrollment after June 30, 2022.

1L, first line; a/m, advanced or metastatic; CT, chemotherapy; DLT, dose-limiting toxicity; IV, intravenous; NSCLC, non-small cell lung cancer; Pt-CT, platinum-based chemotherapy; Q3W, every 3 weeks.

Demographics and Baseline Characteristics, 1L Patients

	All 1L (N=96)	
	Doublet (n=42)	Triplet (n=54)
Age , median (range), years	65 (48–83)	64 (33–78)
Male , n (%)	32 (76.2)	34 (63.0)
Asian race , n (%)	31 (73.8)	23 (42.6)
Histology , n (%)		
Nonsquamous	32 (76.2)	40 (74.1)
Squamous	10 (23.8)	14 (25.9)
History of brain metastases , n (%)	4 (9.5)	10 (18.5)
ECOG PS 1 , n (%)	24 (57.1)	33 (61.1)
Dato-DXd dosing , n (%)		
4 mg/kg	2 (4.8)	22 (40.7)
6 mg/kg	40 (95.2)	32 (59.3)
PD-L1 expression^a , n (%)		
<50%	30 (71.4)	40 (74.1)
≥50%	5 (11.9)	10 (18.5)
NE	7 (16.7)	4 (7.4)

Data cutoff: April 29, 2024.

^aEvaluated using immunohistochemistry (22C3 assay). 1L, first line; ECOG PS, Eastern Cooperative Oncology Group performance status; NE, not evaluable; PD-L1, programmed death ligand 1.


Safety Summary, 1L Patients

Event, n (%)	All 1L (N=96)	
	Doublet (n=42)	Triplet (n=54)
TRAEs	39 (92.9)	54 (100)
Grade ≥3	17 (40.5)	30 (55.6)
Associated with death	0	0
TRAEs associated with dose modifications		
Dose reduction of any drug	8 (19.0)	14 (25.9)
Dose reduction of Dato-DXd	8 (19.0)	7 (13.0)
Discontinuation of any drug	14 (33.3)	20 (37.0)
Discontinuation of Dato-DXd	13 (31.0)	16 (29.6)
Serious TRAEs	5 (11.9)	12 (22.2)
Grade ≥3	4 (9.5)	9 (16.7)
AESIs		
Oral mucositis/stomatitis	26 (61.9)	22 (40.7)
Grade 3	2 (4.8)	1 (1.9)
Adjudicated drug-related ILD/pneumonitis	11 (26.2)	14 (25.9)
Grade 3	2 (4.8)	1 (1.9)
Ocular surface events	9 (21.4)	18 (33.3)
Grade 3	1 (2.4)	2 (3.7)

- Median treatment durations for the doublet and triplet combinations were 6.9 and 5.7 months, respectively
- No grade 4 or 5 AESI events were observed

Data cutoff: April 29, 2024. 1L, first line; AESI, adverse event of special interest; ILD, interstitial lung disease; TRAE, treatment-related adverse event.

TRAEs Occurring in $\geq 20\%$ of 1L Patients




- The most frequent TRAEs of any grade across regimens were nausea, stomatitis, anemia, decreased appetite, and pneumonitis
- Hematologic toxicities occurred more frequently in the triplet cohorts

Data cutoff: April 29, 2024.

1L, first-line; TRAE, treatment-related adverse event.

Efficacy, 1L Doublet


	Doublet (n=42)
Confirmed ORR, n (%)	23 (54.8)
95% CI	38.7–70.2
BOR, n (%)	
CR	1 (2.4)
PR	22 (52.4)
Median DOR, months	20.1
95% CI	9.7–NE
DCR, n (%)	37 (88.1)
95% CI	74.4–96.0
Median TTR, months	1.4
Range	1.2–7.0



Data cutoff: April 29, 2024.
 1L, first line; BOR, best overall response; CI, confidence interval; CR, complete response; DCR, disease control rate; DOR, duration of response; NE, not evaluable; ORR, objective response rate; PR, partial response; TTR, time to response.

Efficacy, 1L Triplet


	Triplet (n=54)
Confirmed ORR, n (%)	30 (55.6)
95% CI	41.4–69.1
BOR, n (%)	
CR	2 (3.7)
PR	28 (51.9)
Median DOR, months	13.7
95% CI	5.7–NE
DCR, n (%)	48 (88.9)
95% CI	77.4–95.8
Median TTR, months	1.4
Range	1.2–9.6



Data cutoff: April 29, 2024.
 1L, first line; BOR, best overall response; CI, confidence interval; CR, complete response; DCR, disease control rate; DOR, duration of response; NE, not evaluable; ORR, objective response rate; PR, partial response; TTR, time to response.


Response by PD-L1 Status^a, 1L Patients

Doublet (n=35)



	PD-L1 <50% (n=30)	PD-L1 ≥50% (n=5)
Median DOR, months	12.0	NE
95% CI	8.0–NE	5.5–NE
DCR, n (%)	29 (96.7)	5 (100)
95% CI	82.8–99.9	47.8–100

Triplet (n=50)




	PD-L1 <50% (n=40)	PD-L1 ≥50% (n=10)
Median DOR, months	14.6	NE
95% CI	5.3–NE	4.1–NE
DCR, n (%)	35 (87.5)	9 (90.0)
95% CI	73.2–95.8	55.5–99.7

Data cutoff: April 29, 2024.
^aEvaluated using immunohistochemistry (22C3 assay).
 1L, first line; CI, confidence interval; DCR, disease control rate; DOR, duration of response; NE, not evaluable; ORR, objective response rate; PD-L1, programmed death receptor-ligand 1.

TROP2 Normalized Membrane Ratio (NMR) Measured by Quantitative Continuous Scoring (QCS)

QCS is a novel, fully-supervised computational pathology approach that precisely quantifies and locates targets like TROP2

- TROP2 Tumor membrane expression using conventional IHC and pathology visual scoring does not enrich for response
- TROP2 NMR as measured by QCS reflects the expression of TROP2 in the membrane relative to total TROP2 (membrane and cytoplasm)




1L, first line; 2L+, second line and beyond; IHC, immunohistochemistry; NMR, normalized membrane ratio; OD, optical density; QCS, quantitative continuous scoring; TROP2, trophoblast cell-surface antigen 2.

TROP2 QCS-NMR positivity was predictive for longer PFS with Dato-DXd in TROPION-Lung01¹

TROP2 QCS-NMR predicted outcomes in an exploratory analysis in the TROPION-Lung01 trial evaluating Dato-DXd as monotherapy in the 2L+ setting¹

Biomarker-evaluable population, n=352




We applied the same cut-off identified for Dato-DXd as 2L+ monotherapy to evaluate enrichment for patient response in the 1L combination setting.

1L, first line; 2L+, second line and beyond; HR, hazard ratio; NMR, normalized membrane ratio; ORR, objective response rate; PFS, progression-free survival; QCS, quantitative continuous scoring; TROP2, trophoblast cell-surface antigen 2.


1. Garassino MC et al. *J Thorac Oncol.* 2024;19:S2–S3.

PFS by TROP2 QCS-NMR, 1L Biomarker Evaluable Population




Data cutoff: April 29, 2024.
BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; NMR, normalized membrane ratio; ORR, objective response rate PFS, progression-free survival; QCS, quantitative continuous scoring; TROP2, trophoblast cell surface antigen 2.

PFS by TROP2 QCS-NMR, 1L Biomarker Evaluable - Doublet



Data cutoff: April 29, 2024.
BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; ORR, objective response rate; PFS, progression-free survival; NMR, normalized membrane ratio; PFS, progression-free survival; QCS, quantitative continuous scoring; TROP2, trophoblast cell surface antigen 2.

PFS by TROP2 QCS-NMR, 1L Biomarker Evaluable - Triplet



Data cutoff: April 29, 2024.
BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; ORR, objective response rate; PFS, progression-free survival; NMR, normalized membrane ratio; PFS, progression-free survival; QCS, quantitative continuous scoring; TROP2, trophoblast cell surface antigen 2.

- At TROPION-Lung02 final analysis, the combination of Dato-DXd + pembrolizumab \pm Pt-CT continued to elicit durable antitumor activity in patients with a/mNSCLC, with efficacy observed in both high and low PD-L1 expression subgroups
- Tolerability of the combinations was as expected based on known profiles of the individual agents
- In this nonrandomized study, exploratory retrospective TROP2 QCS-NMR testing showed a trend towards prolonged PFS in biomarker positive patients for both the doublet and triplet cohorts
- These data support the evaluation of Dato-DXd + pembrolizumab \pm Pt-CT vs standard-of-care therapies in the 1L setting in the ongoing pivotal phase 3 TROPION-Lung07 and TROPION-Lung08 studies

- TROPION-Lung02 was a non-randomized study and comparisons cannot be made between the doublet and triplet cohorts
- Limited sample sizes to clearly interpret the various subgroups of the study (including by PD-L1 status)
- Patients who received different doses of Dato-DXd (4–6 mg/kg) and different chemotherapy drugs (carboplatin/cisplatin) were grouped together to evaluate safety and efficacy
- TROP2 biomarker analyses were conducted retrospectively with the evolving development of QCS as a novel computational approach to assess TROP2 expression patterns in NSCLC

Neoadjuvant durvalumab + chemotherapy + novel anticancer agents and adjuvant durvalumab \pm novel agents in resectable NSCLC: Updated outcomes from NeoCOAST-2

Tina Cascone,¹ Laura Bonanno,^{2,3} Florian Guisier,⁴ Amelia Insa,⁵ Moishe Liberman,^{6,7} Olivier Bylicki,^{8,9} Lorenzo Livi,¹⁰ Thomas Egenod,¹¹ Romain Corre,¹² Agata A Bielska,¹³ Alula R Yohannes,¹⁴ Yun He,¹³ Adam Dowson,¹⁵ Lara McGrath,¹³ Gozde Kar,¹⁵ Rakesh Kumar,¹⁴ Italia Grenga,¹³ Jonathan Spicer,¹⁶ Patrick M Forde¹⁷

¹Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy; ³Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; ⁴Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Department of Pneumology and Inserm CIC-CRB 1404, Rouen, France; ⁵Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain; ⁶Division of Thoracic Surgery, University of Montréal, Montréal, QC, Canada; ⁷CETOC - CHUM Endoscopic Tracheobronchial and Oesophageal Center, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; ⁸Respiratory Medicine Department, Hôpital d'Instruction des Armées Sainte-Anne, Toulon, France; ⁹Ecole du val de Grace, Paris, France; ¹⁰Department of Radiation Oncology, University of Florence, Florence, Italy; ¹¹Department of Thoracic Oncology, Dupuytren University Hospital, Limoges, France; ¹²Department of Medical Oncology, CH de Cornouaille, Quimper, France; ¹³AstraZeneca, Waltham, MA, USA; ¹⁴AstraZeneca, Gaithersburg, MD, USA; ¹⁵AstraZeneca, Cambridge, UK; ¹⁶Department of Thoracic Surgery, McGill University, Montréal, QC, Canada; ¹⁷Trinity St. James's Cancer Institute, Trinity College Dublin, Ireland (*Affiliation at time of abstract preparation: Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA)

Figure 1. NeoCOAST-2 study design




Table 1. Baseline demographic and disease characteristics (mITT population)

Parameter	Arm 1 Durvalumab + oleclumab + CT (N=74)	Arm 2 Durvalumab + monalizumab + CT (N=70)	Arm 4 Durvalumab + Dato-DXd + Plt (N=54)
Median age (range), years	66.5 (30–79)	66.0 (48–83)	65.0 (38–81)
Male / Female, n (%)	46 (62.2) / 28 (37.8)	42 (60.0) / 28 (40.0)	32 (59.3) / 22 (40.7)
Smoking status, n (%)			
Current / former / never	15 (20.3) / 55 (74.3) / 4 (5.4)	22 (31.4) / 46 (65.7) / 2 (2.9)	15 (27.8) / 36 (66.7) / 3 (5.6)
Race, n (%)			
White	46 (62.2)	42 (60.0)	37 (68.5)
Asian	7 (9.5)	5 (7.1)	5 (9.3)
Black or African American	1 (1.4)	0	0
Not reported	20 (27.0)	23 (32.9)	12 (22.2)
ECOG PS 0 / 1, n (%)*	45 (61.6) / 28 (38.4)	48 (68.6) / 22 (31.4)	35 (64.8) / 19 (35.2)
PD-L1 TPS <1% / ≥1%, n (%)†	25 (33.8) / 49 (66.2)	28 (40.0) / 42 (60.0)	16 (29.6) / 38 (70.4)
Planned platinum agent, n (%)			
Carboplatin / cisplatin	53 (71.6) / 21 (28.4)	55 (78.6) / 15 (21.4)	47 (87.0) / 7 (13.0)
Stage, n (%)			
IIA / IIB	7 (9.5) / 15 (20.3)	8 (11.4) / 17 (24.3)	2 (3.7) / 13 (24.1)
IIIA / IIIB	38 (51.4) / 14 (18.9)	32 (45.7) / 13 (18.6)	28 (51.9) / 11 (20.4)
Histology, n (%)			
Adenocarcinoma	49 (66.2)	46 (65.7)	33 (61.1)
Squamous cell carcinoma	23 (31.1)	19 (27.1)	17 (31.5)
Other‡	2 (2.7)	5 (7.1)	4 (7.4)

*Percentages calculated with the number of patients with reported performance status as denominator; †Based on central results for 70.3%, 75.7%, and 63.0% of patients and local results for 29.7%, 24.3%, and 37.0% of patients in Arms 1, 2, and 4, respectively; ‡Arm 1: carcinoma, type not determined (n=2); Arm 2: carcinoma, type not determined (n=1), other (n=4); Arm 4: large cell carcinoma (n=2), carcinoma, type not determined (n=1), other (n=1).
CT, platinum-doublet chemotherapy; Dato-DXd, datopotamab deruxtecan; ECOG PS, Eastern Cooperative Oncology Group Performance Status; mITT, modified intention-to-treat; PD-L1, programmed cell death ligand-1; Plt, single-agent platinum chemotherapy; TPS, tumor proportion score

Patient disposition and characteristics

- At DCO (19 December, 2024), all patients in Arms 1, 2, and 4 had the opportunity to complete neoadjuvant therapy and receive surgery.
- 202 patients were randomized (ITT population), of whom 199 were in the safety population and 198 were in the mITT population.
 - Table 1** shows baseline demographics and disease characteristics in the mITT population and **Figure 2** shows patient disposition in the ITT population.
- Approximately half of patients had Stage IIIA NSCLC and two-thirds had a programmed cell death ligand-1 (PD-L1) tumor proportion score (TPS) ≥1%.

Figure 3. pCR and mPR rates across arms (mITT population, per central BIPR)





Figure 4. pCR and mPR rates by tumoral PD-L1 expression across arms (mITT population, per central BIPR)



Efficacy

- pCR and mPR rates at final analysis are shown in **Figure 3**.
- In Arms 1 and 2, pCR and mPR rates were numerically higher in patients with PD-L1 TPS ≥1% vs <1%; in Arm 4, pCR and mPR rates were similar in patients with PD-L1 TPS ≥1% or <1% (**Figure 4**).
- Higher pCR and mPR rates were seen in patients with squamous cell carcinoma vs adenocarcinoma in all arms (**Figure 5**).

Figure 5. pCR and mPR rates by tumor histology across arms (mITT population, per central BIPR)





Table 4. Safety summary in Arm 4 (durvalumab + Dato-DXd + Pt)

n (%)	Neoadjuvant (N=54)	Post-surgery (N=51)	Adjuvant (N=47)
Any TEAE	53 (98.1)	32 (62.7)	40 (85.1)
Any TRAE	52 (96.3)	8 (15.7)	28 (55.3)
Grade ≥3 TEAE	13 (24.1)	7 (13.7)	8 (17.0)
Grade ≥3 TRAE	10 (18.5)	1 (2.0)	3 (6.4)
TEAE leading to discontinuation of any study treatment	6 (11.1)	1 (2.0)	0
SAE	10 (18.5)	7 (13.7)	5 (10.6)
SAE with outcome of death	0	1 (2.0)*	1 (2.1) [†]

*Due to idiopathic pulmonary fibrosis unrelated to treatment as per the principal investigator and related to study treatment per independent adjudicator; [†] Infectious endocarditis, not related to any drugs or surgery.
Dato-DXd, datoprotamab deruxtecan; Pt, single-agent platinum chemotherapy; SAE, serious adverse event; TEAE, treatment-emergent adverse event; TRAE, treatment-related adverse event.

Figure 8. TEAEs occurring in ≥10% of patients in Arm 4 in the neoadjuvant period*



Safety

- At DCO (19 Dec 2024), the median (range) duration of safety follow-up was 11.2 (3.5–15.7) months in Arm 4.
- Safety data are summarized in Table 4 (Arm 4).
- The most common TEAEs are summarized in Figure 8 (Arm 4).

Conclusions

- Results showed a numerically higher pCR rate in Arm 4 compared to current standard-of-care options and promising mPR rates.
- Data from Arm 4 showed manageable safety and maintained feasibility of surgery of novel perioperative combinations.
- Encouraging pathological response rates were observed in both PD-L1 subgroups in Arm 4.
- The pCR and mPR rates in Arm 4 are the first reported for an antibody-drug conjugate in the neoadjuvant setting and confirm the encouraging efficacy and manageable safety profile of neoadjuvant durvalumab + Dato-DXd + Plt in this context.
- Presurgical ctDNA clearance was associated with pathological responses in all arms, with the numerically highest rate of ctDNA clearance observed in Arm 4.
- NeoCOAST-2 is ongoing, including newly added arms assessing (1) neoadjuvant rilvegostomig + CT and adjuvant rilvegostomig, and (2) neoadjuvant Dato-DXd + rilvegostomig + Plt and adjuvant rilvegostomig.
- A manuscript containing the full efficacy and safety data for the arms described in this poster has been published simultaneously in Nature Medicine: <https://doi.org/10.1038/s41591-025-03746-z>

HER3-DXd

Patritumab Deruxtecan (HER3-DXd) in Resistant *EGFR*-Mutated Advanced NSCLC After a Third-Generation EGFR TKI: The Phase 3 HERTHENA-Lung02 Study


Tony S. K. Mok, MD, FRCPC, FASCO

Department of Clinical Oncology, State Key Laboratory of Translational Oncology and The Chinese University of Hong Kong, Hong Kong, Hong Kong PRC

Additional authors: Helena A. Yu, MD, Sun Min Lim, MD, PhD, Isamu Okamoto, MD, PhD, Maurice Pérol, MD, Silvia Novello, MD, PhD, Christophe Doods, MD, PhD, Jong-Mu Sun, PhD, Steven Kao, BHB, MBChB, PhD, FRACP, Pasi A. Jänne, MD, PhD, Martin Reck, MD, PhD, Conor Steuer, MD, Makoto Nishio, MD, PhD, Yi-Long Wu, MD, Ronan Fougeray, MS, Ragini Kudchadkar, MD, Jian Yu Wu, Stephen Esker, PharmD, Antonio Passaro, MD, PhD

Study Design

HERTHENA-Lung02: A phase 3, global, multi-center, randomized, open-label study¹



AUC5, area under the curve of 5 mg/mL·min; BICR, blinded independent central review; CNS, central nervous system; EGFR, epidermal growth factor receptor; HER3, human epidermal growth factor receptor 3; IHC, immunohistochemistry; IV, intravenous; NSCLC, non-small cell lung cancer; OS, overall survival; PBC, platinum-based chemotherapy; PFS, progression-free survival; Q3W, every 3 weeks; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor.

^a No limit to the number of cycles of pemetrexed, as it is given as maintenance as per labeling. ^b Brain imaging was centrally assessed by a separate, blinded group of neuro-oncologists (CNS BICR) according to the CNS RECIST criteria.²

1. Mok TSK, et al. *Future Oncol.* 2024;20(15):969-980. 2. Yu HA, et al. *J Clin Oncol.* 2023;41(35):5363-5375.

Statistical analyses

Sample size

- The planned enrollment of 560 patients was chosen to provide:
 - ≈99% power to detect an HR of 0.64 in **PFS** at the **final analysis** (at ≈**363 events**)
 - And subsequently (assuming a statistically significant difference in PFS),
 - ≈80% power to detect an HR of 0.75 in **OS** at the **final analysis** (at ≈**393 events**)


Primary endpoint (PFS by BICR)

- At the **PFS primary analysis** (DCO May 31, 2024), **389 PFS events** had occurred
 - 127 patients remained on treatment (84 on HER3-DXd and 43 on PBC)
 - Median follow-up was 8.5 months in the HER3-DXd arm and 8.3 months in the PBC arm
- Stopping boundary:
 - Efficacy boundary for superiority: $P < 0.04998$

Key secondary endpoint (OS)

- At the 3rd interim OS analysis (DCO Feb 28, 2025) data were mature, with 327 events
 - OS information fraction, 83% (327 of 393 events)
 - Median follow-up was 18.7 months in the HER3-DXd arm and 18.6 months in the PBC arm

Hierarchical testing



Baseline population characteristics were balanced across treatment arms and were typical of patients with *EGFR*-mutated NSCLC in this treatment line


Baseline characteristics		HER3-DXd (N=293)	PBC (N=293)
Age, median (range), years		64 (35-82)	64 (34-86)
Female, n (%)		184 (62.8)	175 (59.7)
Asian, n (%)		176 (60.1)	178 (60.8)
Smoking history, n (%)	Never	187 (63.8)	185 (63.1)
	Ever	106 (36.2)	108 (36.9)
Time since initial NSCLC diagnosis, median (range), months		24.2 (2.5-121.1)	24.1 (3.2-146.1)
ECOG PS at baseline, n (%)	0	110 (37.5)	102 (34.8)
	1	183 (62.5)	190 (64.8)
	2 ^a	0	1 (0.3)
History of brain metastasis, n (%) ^b		127 (43.3)	132 (45.1)
Brain metastasis at baseline (by CNS BICR per CNS RECIST), n (%) ^c		105 (35.8)	95 (32.4)
<i>EGFR</i> activating mutations, n (%)	Ex19del	177 (60.4)	178 (60.8)
	L858R	113 (38.6)	112 (38.2)
	Dual Ex19del and L858R	3 (1.0)	3 (1.0)
Prior <i>EGFR</i> TKI, n (%)	Only 3rd-generation	225 (76.8)	223 (76.1)
	3rd- and 1st/2nd-generation	68 (23.2)	70 (23.9)
Line of treatment for prior 3rd-generation <i>EGFR</i> TKI, n (%)	First line	226 (77.1)	227 (77.5)
	Second line	67 (22.9)	66 (22.5)
Type of prior 3rd-generation <i>EGFR</i> TKI, n (%)	Osimertinib	266 (90.8)	263 (89.8)
	Other 3rd-generation ^d	27 (9.2)	30 (10.2)

BICR, blinded independent central review; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; *EGFR*, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PBC, platinum-based chemotherapy; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor.

^a All patients had an ECOG PS of 0 or 1 at screening. ^b Including brain metastases that were previously treated. ^c Brain imaging was centrally assessed by a separate, blinded group of neuro-oncologists (CNS BICR) according to the CNS RECIST criteria.

^d Aumolertinib, befotertinib, furmonertinib, and lazertinib.

HER3-DXd significantly reduced the risk of disease progression (by BICR per RECIST 1.1) or death vs PBC




Data cutoff May 31, 2024. Median follow-up: HER3-DXd, 8.5 months (95% CI, 8.2-10.9 months); PBC, 8.3 months (95% CI, 6.9-8.8 months).

BICR, blinded independent central review; HR, hazard ratio; ITT, intention to treat; PBC, platinum-based chemotherapy; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.

^a For disease progression or death. Cox proportional hazards model stratified by randomization stratification factors. ^b Stratified log-rank test, ITT population; efficacy boundary for superiority, $P<0.04998$.

The PFS benefit observed was generally consistent across subgroups




Data cutoff May 31, 2024.

BICR, blinded independent central review; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; HR, hazard ratio; PBC, platinum-based chemotherapy; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.

Observed efficacy by ORR confirmed previous observations in later treatment lines

Responses by BICR per RECIST		HER3-DXd (N=293)	PBC (N=293)
Confirmed ORR (95% CI), %		35.2 (29.7-40.9)	25.3 (20.4-30.6)
Best overall response, n (%)	CR	1 (0.3)	3 (1.0)
	PR	102 (34.8)	71 (24.2)
	SD ^a	133 (45.4)	148 (50.5)
	PD	40 (13.7)	35 (11.9)
	NE	17 (5.8) ^b	36 (12.3) ^c
BOR to be confirmed, n (%)		2 (0.7) ^d	2 (0.7) ^d
DCR (95% CI), %		80.5 (75.5-84.9)	75.8 (70.4-80.6)
Median TTR (range), mo		1.5 (0.3-8.1)	1.5 (1.2-6.9)
Median DOR (95% CI), mo		5.7 (5.1-7.3)	5.4 (4.1-5.6)



Data cutoff May 31, 2024.

BICR, blinded independent central review; BOR, best overall response; CR, complete response; DCR, disease control rate; DOR, duration of response; NE, not evaluable; ORR, objective response rate (CR or PR confirmed ≥ 4 weeks after initial response [per RECIST 1.1]); PBC, platinum-based chemotherapy; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SOD, sum of diameters; TTR, time to response. ^a Includes non-CR/non-PD.

^b No adequate postbaseline tumor assessment (n=15); SD too early (SD <5 weeks after randomization; n=2). ^c No adequate postbaseline tumor assessment (n=30); SD too early (SD <5 weeks after randomization; n=5); PD too late (PD >12 weeks after randomization; n=1). ^d All were unconfirmed PR in patients who were ongoing without disease progression.

The safety profile of HER3-DXd was generally manageable and was consistent with previously reported trials

Safety Summary

All cause TEAEs	HER3-DXd (n=290)	PBC (n=280)
Any, n (%)	290 (100)	277 (98.9)
Grade ≥3	211 (72.8)	160 (57.1)
Treatment related	168 (57.9)	129 (46.1)
Serious	124 (42.8)	80 (28.6)
Treatment related	65 (22.4)	35 (12.5)
Associated with treatment discontinuation	33 (11.4)	27 (9.6)
Associated with dose reduction	94 (32.4)	59 (21.1)
Associated with dose interruption	131 (45.2)	105 (37.5)
Associated with death	22 (7.6)	14 (5.0)
Treatment related	4 (1.4) ^a	1 (0.4) ^b
Median treatment duration (range), months	5.5 (0.7-16.8)	4.6 (0.7-16.5)


Data cutoff May 31, 2024.

PBC, platinum-based chemotherapy; TEAE, treatment emergent adverse event.

^a Interstitial lung disease/pneumonitis (n=2), pneumonia (n=1), and septic shock (n=1), per investigator assessment.

^b Cerebral hemorrhage (n=1), per investigator assessment.

The safety profile of HER3-DXd was generally manageable and was consistent with previously reported trials



Data cutoff May 31, 2024.
 ALT, alanine aminotransferase; AST, aspartate aminotransferase; PBC, platinum-based chemotherapy; PT, preferred term; TEAE, treatment emergent adverse event.

The incidence of adjudicated ILD was consistent with previous studies, with most events being grade 1 or 2

- ILD, adjudicated by an independent committee,^a occurred in 5.2% of patients treated with HER3-DXd
 - Median time to first onset was 126 days (range 29-304 days)
 - ILD was associated with dose interruption in 4 patients (1.4%), treatment discontinuation in 12 (4.1%), and death in 2 (0.7%)

ILD Adjudication, n (%)	Grade by <i>investigator</i> or adjudication committee					
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total ILD
HER3-DXd (n=290)						
<i>Patients with Potential ILD Events (per investigator)</i>	8 (2.8)	13 (4.5)	3 (1.0)	0	4 (1.4)	28 (9.7)
Adjudicated as ILD	2 (0.7)	10 (3.4)	1 (0.3)	0	2 (0.7)	15 (5.2)
Adjudicated as treatment-related ILD	2 (0.7)	9 (3.1)	1 (0.3)	0	2 (0.7)^b	14 (4.8)
PBC (n=280)						
<i>Patients with Potential ILD Events (per investigator)</i>	1 (0.4)	0	0	1 (0.4)	0	2 (0.7)
Adjudicated as ILD	0	0	0	0	0	0
Adjudicated as treatment-related ILD	0	0	0	0	0	0

- ILD is acknowledged as an AE of Special Interest and well-established treatment management guidelines are in place

Data cutoff May 31, 2024.


AE, adverse event; ILD, interstitial lung disease; PBC, platinum-based chemotherapy.

^a The ILD adjudication committee consists of 15 physicians, including radiologists, pulmonologists, and oncologists. A panel with a representative from each specialty reviews all clinical and radiographic data to make an independent assessment of each case.

^b Patient 1: 75-year-old woman, pneumonia. Course was consistent with disease progression with superimposed drug toxicity. Patient 2: 71-year-old man, ILD. Treated with steroid and antibiotic therapies.

Newly available mature data from extended follow-up (data cutoff: Feb 28, 2025)^a

OS for patients treated with HER3-DXd compared to PBC



Median follow-up: HER3-DXd, 18.7 months (95% CI, 17.9-19.9 months); PBC, 18.6 months (95% CI, 17.9-19.6 months).

HR, hazard ratio; OS, overall survival; PBC, platinum-based chemotherapy.

^a 327 of 393 events had occurred; information fraction, 83%. ^b For death from any cause. Cox proportional hazards model stratified by randomization stratification factors.

Conclusions

- Primary analysis of the HERTHENA-Lung02 study demonstrated a statistically significant improvement in PFS for HER3-DXd vs PBC in patients with *EGFR*-mutated NSCLC that progressed on third-generation TKI therapy (HR 0.77, $p=0.011$)
- Newly available 3rd interim analysis demonstrated that OS for patients treated with HER3-DXd did not show an improvement compared to those receiving PBC^a
- HER3-DXd monotherapy demonstrated intracranial antitumor activity
 - Intracranial ORR (95% CI) and median intracranial PFS (95% CI) were 19.0% (12.0%-27.9%) and 5.4 months (4.0-5.9 months) with HER3-DXd vs 11.6% (5.9%-19.8%) and 4.2 months (2.8-5.0 months) with PBC
- The safety profile of HER3-DXd was generally manageable, consistent with previous reports
 - Most common TEAEs were hematologic and gastrointestinal
 - The incidence of adjudicated ILD was 5.2%
- Evaluation of the association of biomarkers, including HER3 IHC, with efficacy parameters in HERTHENA-Lung02 and their suitability as a predictive biomarker is ongoing

EGFR, epidermal growth factor receptor; HER3, human epidermal growth factor receptor 3; HR, hazard ratio; IHC, immunohistochemistry; ILD, interstitial lung disease; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PBC, platinum-based chemotherapy; PFS, progression-free survival; TEAE, treatment-emergent adverse event; TKI, tyrosine kinase inhibitor.

^a HERTHENA-Lung02 is an ongoing trial, and further results regarding key secondary data will be presented at a future congress.

HER3-DXd : Clinical Studies

Ph2 (Ph1/2)

Ph1

NSCLC	EGFRm	1L/2L, osimertinib combo	
	Non-AGA	KEYMAKER-U01 substudy 01A 1L, pembrolizumab combo	KEYMAKER-U01 substudy 01G 1L, pembrolizumab combo
BC	HER2+	HERTHENA-Breast01 2L+	
	TNBC	HERTHENA-Breast03* high-risk early stage, neoadjuvant pembrolizumab combo	
Other tumors		HERTHENA-PanTumor01	HERTHENA-PanTumor02

*HERTHENA-Breast03 includes high-risk early stage HR low and HER2 negative breast cancer

BC: breast cancer, EGFRm: EGFR mutated, HR: hormone receptor, NSQ: non-squamous, NSCLC: non-small cell lung cancer, TNBC: triple negative breast cancer

Next Wave

A Phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T-cell engager, in patients with advanced solid tumors


Sandra P. D'Angelo,¹ Vivek Subbiah,² Jean-Yves Blay,³ Michael J. Wagner,⁴ Neeltje Steeghs,⁵ Jeonghwan Youk,⁶ Hideki Mizusako,⁷ Yoshihiro Ohue,⁸ Jin Jin,⁸ Abdul Waheed Rajper,⁸ Nicole Tesar,⁸ Patrick Schöffski⁹

1 Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2 Sarah Cannon Research Institute, Nashville, TN, USA; 3 Centre Léon Bérard, Lyon, France; 4 Dana-Farber Cancer Institute, Boston, MA, USA; 5 Netherlands Cancer Institute, Amsterdam, The Netherlands; 6 Seoul National University Hospital, Seoul, South Korea; 7 Daiichi Sankyo Co., Ltd., Tokyo, Japan; 8 Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; 9 Universitaire Ziekenhuizen Leuven, Leuven, Belgium.

DS-2243, a New T-cell Engager

A Potential First-in-Class **Bispecific T-cell Engager (Bi-TCE)** Targeting HLA-A*02/NY-ESO Tumors

Mode of Action



- **Cutting-Edge Bi-TCE:** Engineered to selectively engage both tumor antigens and T-cells, driving a targeted and potent immune response.
- **Tumor-Specific Targeting:** Precise targeting through the HLA-A*02/NY-ESO complex mediated by NY-ESO, a highly tumor-specific antigen. NY-ESO is only expressed in the testis in normal tissue, where it is present without HLA-A molecules.
- **Broad Applicability:** High/moderate frequency of NY-ESO expression observed in Synovial Sarcoma, Myxoid/Round Cell Liposarcoma, NSCLC, UC etc.
- **Promising Efficacy:** Exhibits robust anti-tumor activity and significant combination therapy potential in preclinical studies.

Agenda

① Welcome message

② R&D overview

③ Highlights from ASCO 2025

④ Q&A



Contact address regarding this material

Daiichi Sankyo Co., Ltd.

Corporate Communications Department

TEL: +81-3-6225-1125

Email: DaiichiSankyoIR_jp@daiichisankyo.com